Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Aggression × midostaurin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13 Neoplasm, Residual 2 Mastocytosis, Systemic 2 Leukemia, Mast-Cell 2 Leukemia 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Congenital Abnormalities 1 Aggression 1

Interventions

vandetanib 1 midostaurin 1 glofitamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed

116 enrolled 16 charts

LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡